Latest News

Stay up to date on the latest news brought to you in collaboration with leading experts

View all Articles

Study: Physicians Should Prioritize Weight Management in Breast Cancer Care to Boost Survival Rates

A new study underscores the importance of weight counseling in breast cancer. Gains and losses are associated with lower chance of survival, especially in patients who undergo chemotherapy.

Learn More

Study Raises Clinical Considerations for Strategic Immunotherapy Use in Metastatic Cancer Care

New Yale study finds a significant rise in the use of immunotherapy in late-stage cancer, highlighting its growing use in end-of-life care and a greater success rate at larger institutions.

Learn More

Nearly 50% Skip Prescribed Breast Cancer Meds; Physicians Should Focus On Cost Cutting and Education

A new study suggests that cost-reduction policies and targeted interventions significantly increase adjuvant endocrine therapy adherence among breast cancer survivors.

Learn More

HER2-Low, A New Classification Of Breast Cancer, Expands The Use Of Enhertu For Metastatic Patients

Contributed by Dr. Muneeb Niazi, Medical Fellow at SurvivorNet. Trastuzumab deruxtecan (brand name: Enhertu) is a Food and Drug Administration (FDA) approved drug for certain stage four breast cancer patients whose tumors are classified as HER2- low. Previous therapies targeting cancer tumors with HER2 (Human Epidermal Growth Factor 2)-low proteins, such as trastuzumab (brand name: […]

Learn More

Criteria and Considerations for Using Newly FDA-Approved Lifileucel in Advanced Melanoma

FDA grants accelerated approval for lifileucel, a TIL therapy for advanced melanoma, marking a first for a cellular therapy targeting a solid tumor.

Learn More

Tepmetko Approval for NSCLC Mutation Underscores the Value of Genetic Testing

Clinical Relevance: Tepotinib’s approval marks a pivotal advancement in targeted therapy for NSCLC, offering a highly specific treatment option for patients with MET exon 14 skipping mutations and underscoring the importance of genetic profiling in modern oncology practice. _________________________________________________________________________________________________ The availability of Tepmetko (tepotinib), should prompt ontologists to order genetic testing for all of their […]

Learn More

Balversa’s FDA Approval Means a New, Practice-Changing Option for FGFR-Positive Bladder Cancer

Clinical Relevance: Newly FDA-approved Balversa offers a targeted treatment option for patients with FGFR3-positive metastatic bladder cancer, demonstrating significant efficacy in progression-free and overall survival rates, and should be considered post platinum-containing chemotherapy or anti-PD-(L)1 therapy failures. _________________________________________________________________________________________________ Oncologists now have a new option to consider in their decision-making process thanks to the full US […]

Learn More

The Evolving Management of Anemia in Myelofibrosis

Contributed by Dr. Muneeb Niazi, Medical Fellow at SurvivorNet. Myelofibrosis (MF) belongs to a group of blood cancers called myeloproliferative neoplasms (MPNs). These cancers originate in the myeloid tissue, commonly known as the bone marrow, which lines the inside of large bones, such as the vertebral column or the hip bones. “The [abnormal] cell of […]

Learn More

BTK Inhibitor Jaypirca is Now FDA-Approved & May Help Difficult-to-Treat Mantle Cell Lymphoma

Contributed by Dr. Muneeb Niazi, Medical Fellow at SurvivorNet. Mantle Cell Lymphomas (MCL) are rare blood cancers that affect the white blood cells (WBCs), one of the main cell types within the blood. These cancers are as aggressive as they are rare. Treating them can often prove to be an uphill battle. They often reoccur […]

Learn More

Elacestrant (Orserdu) Is Effective For A Stubborn Form of Metastatic Breast Cancer

Contributed by Dr. Muneeb Niazi, Medical Fellow at SurvivorNet. For some women with a particular type of advanced, or metastatic, breast cancer, a new treatment option is showing really promising results. Metastatic breast cancer can be hard to treat, especially when some of the traditional hormone/endocrine therapies do not work. This may happen with particular […]

Learn More

Elahere Has Become A Practice-Changing Option for Platinum-Resistant, FRα Ovarian Cancer

FDA-approved Elahere for FRα-positive, platinum-resistant ovarian cancer offers new hope with its targeted mechanism and positive trial results. ​

Learn More

Ibrutinib For Mantle Cell Lymphoma

Mantle cell lymphoma (MCL) is a rare but deadly form of non-Hodgkin lymphoma, a blood cancer affecting the white blood cells (WBCs). It tends to be aggressive and is usually diagnosed later in the disease course, when it is often resistant to treatment. Traditional treatment with the best chance for long-term disease control for MCL […]

Learn More

When To Treat Chronic Lymphocytic Leukemia (CLL)?

Contributed by Dr. Muneeb Niazi, Medical Fellow at SurvivorNet. Chronic Lymphocytic Leukemia (CLL) is a slow-going or “indolent” blood cancer. Despite being cancer, it is one of those counterintuitive diseases for which delaying treatment can surprisingly be the most appropriate “treatment” option. Studies show that many patients with this disease can live long, fulfilling lives […]

Learn More

Active Surveillance For Chronic Lymphocytic Leukemia (CLL)

Contributed by Dr. Muneeb Niazi, Medical Fellow at SurvivorNet. Chronic Lymphocytic Leukemia (CLL) is a slow-growing cancer of the white blood cells (WBCs). This specific type of cancer has great, effective treatment options Moreover, some patients, especially those in the early, asymptomatic stages of the disease, may be able to live for long periods of […]

Learn More

Viewpoints

Clinical developments explained by the country's leading voices on cancer care

View all Articles

Tepmetko Approval for NSCLC Mutation Underscores the Value of Genetic Testing

Clinical Relevance: Tepotinib’s approval marks a pivotal advancement in targeted therapy for NSCLC, offering a highly specific treatment option for patients with MET exon 14 skipping mutations and underscoring the importance of genetic profiling in modern oncology practice. _________________________________________________________________________________________________ The availability of Tepmetko (tepotinib), should prompt ontologists to order genetic testing for all of their […]

Learn More

Physicians Advised to Consider Rybrevant for EGFR Mutation-Positive NSCLC, Following FDA Approval

Rybrevant receives FDA approval as a game-changing treatment for NSCLC with specific genetic mutations, marking a significant advancement in personalized cancer therapy.

Learn More

Criteria and Considerations for Using Newly FDA-Approved Lifileucel in Advanced Melanoma

FDA grants accelerated approval for lifileucel, a TIL therapy for advanced melanoma, marking a first for a cellular therapy targeting a solid tumor.

Learn More

Nearly 50% Skip Prescribed Breast Cancer Meds; Physicians Should Focus On Cost Cutting and Education

A new study suggests that cost-reduction policies and targeted interventions significantly increase adjuvant endocrine therapy adherence among breast cancer survivors.

Learn More

Integrating Venetoclax Into CLL Management Is Expanding Treatment Horizons and Improving Survival

Clinical Relevance: Venetoclax can offer your CLL patients a powerful, targeted treatment that is personalized and more effective care with fewer side effects than many other options. _________________________________________________________________________________________________________ Oncologists treating chronic lymphocytic leukemia (CLL) and select small lymphocytic lymphomas should strongly consider adding Venetoclax (Venclexta) to their arsenal, given its proven capacity to significantly enhance […]

Learn More

Balversa’s FDA Approval Means a New, Practice-Changing Option for FGFR-Positive Bladder Cancer

Clinical Relevance: Newly FDA-approved Balversa offers a targeted treatment option for patients with FGFR3-positive metastatic bladder cancer, demonstrating significant efficacy in progression-free and overall survival rates, and should be considered post platinum-containing chemotherapy or anti-PD-(L)1 therapy failures. _________________________________________________________________________________________________ Oncologists now have a new option to consider in their decision-making process thanks to the full US […]

Learn More

Elahere Has Become A Practice-Changing Option for Platinum-Resistant, FRα Ovarian Cancer

FDA-approved Elahere for FRα-positive, platinum-resistant ovarian cancer offers new hope with its targeted mechanism and positive trial results. ​

Learn More

Study Raises Clinical Considerations for Strategic Immunotherapy Use in Metastatic Cancer Care

New Yale study finds a significant rise in the use of immunotherapy in late-stage cancer, highlighting its growing use in end-of-life care and a greater success rate at larger institutions.

Learn More

Oral Azacitidine May Increase Survival in Older Patients with AML

Maintenance therapy with the oral version of azacitidine (brand name: ONUREG) significantly improves disease-free survival in older adults with acute myeloid leukemia (AML) who have achieved complete remission on intensive chemotherapy, according to research published in the journal Blood. This is the first time a maintenance therapy has shown a survival advantage in older adults, who make up the vast majority of AML patients.

Learn More

Study: Physicians Should Prioritize Weight Management in Breast Cancer Care to Boost Survival Rates

A new study underscores the importance of weight counseling in breast cancer. Gains and losses are associated with lower chance of survival, especially in patients who undergo chemotherapy.

Learn More

The Evolution to BTK Inhibitors in CLL Treatment

Chronic lymphocytic leukemia (CLL) treatment used to be one-size-fits-all. Today, the approach has shifted to more targeted therapies, thanks to the introduction of the Bruton's tyrosine kinase (BTK) inhibitors. Dr. James Gerson, hematologist-oncologist at Penn Medicine, tells SurvivorNet Connect that he prefers acalabrutinib (brand name: Calquence) because it has fewer side effects than ibrutinib in a similar patient population.

Learn More

Metastatic Lung Cancer — Deciding on Next Steps

Biomarker testing can guide you to the initial targeted treatment for patients with metastatic lung cancer, but what happens when that first-line treatment stops holding the cancer at bay? Dr. Patrick Forde, thoracic oncologist at Johns Hopkins, suggests retesting to find a new therapeutic target.

Learn More

Should CAR T-Cell Therapy be the Standard Third Line Treatment for Non-Hodgkin Lymphoma?

“If you don’t think of CAR T-cell therapy as a third line of therapy, you’re malpracticing,” Dr. Stephen Schuster, Penn Medicine hematologist/oncologist, tells SurvivorNet Connect. His concern is that, “It’s not yet gelled in the mind of all practicing oncologists that this is a reality for their patients.” Dr. Schuster is eager to raise awareness of CAR T-cell therapy because its success as third line therapy depends in large part on earlier therapeutic choices.

Learn More

Bispecific Antibodies Offer Lymphoma Patients a Promising New Therapeutic Option

Bispecific antibodies have exciting potential as a cancer therapy, due to their ability to simultaneously bind to two targets. Right now, this treatment is only available in investigational trials, but it has shown promising outcomes for patients with relapsed-refractory lymphoma who have already undergone a transplant, CAR T-cell therapy, or other lines of treatment.

Learn More

Belamaf is ‘First-In-Class’ New Therapy for Relapsed/Refractory Myeloma, But What’s Its Role in the Toolkit?

In August, the FDA granted belantamab mafodotin (Belamaf) accelerated approval for patients with relapsed or refractory multiple myeloma who've received at least four prior therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent.

Learn More

Calquence (Acalabrutinib) Has an Advantage Over Other BTK Inhibitors in CLL Treatment

Bruton tyrosine kinase (BTK) inhibitors have proven themselves highly effective for both treatment-naïve and relapsed/refractory chronic lymphocytic leukemia (CLL). The first-generation BTK inhibitor ibrutinib was followed by second-generation drugs such as acalabrutinib (brand name: Calquence), zanubrutinib and tirabrutinib, which have all shown good long-term efficacy and safety.

Learn More

CLINICAL UPDATES

Practical guidance for newly approved therapies

View all Articles

Criteria and Considerations for Using Newly FDA-Approved Lifileucel in Advanced Melanoma

FDA grants accelerated approval for lifileucel, a TIL therapy for advanced melanoma, marking a first for a cellular therapy targeting a solid tumor.

Learn More

Physicians Advised to Consider Rybrevant for EGFR Mutation-Positive NSCLC, Following FDA Approval

Rybrevant receives FDA approval as a game-changing treatment for NSCLC with specific genetic mutations, marking a significant advancement in personalized cancer therapy.

Learn More

Balversa’s FDA Approval Means a New, Practice-Changing Option for FGFR-Positive Bladder Cancer

Clinical Relevance: Newly FDA-approved Balversa offers a targeted treatment option for patients with FGFR3-positive metastatic bladder cancer, demonstrating significant efficacy in progression-free and overall survival rates, and should be considered post platinum-containing chemotherapy or anti-PD-(L)1 therapy failures. _________________________________________________________________________________________________ Oncologists now have a new option to consider in their decision-making process thanks to the full US […]

Learn More

Tepmetko Approval for NSCLC Mutation Underscores the Value of Genetic Testing

Clinical Relevance: Tepotinib’s approval marks a pivotal advancement in targeted therapy for NSCLC, offering a highly specific treatment option for patients with MET exon 14 skipping mutations and underscoring the importance of genetic profiling in modern oncology practice. _________________________________________________________________________________________________ The availability of Tepmetko (tepotinib), should prompt ontologists to order genetic testing for all of their […]

Learn More

PATIENT CARE UPDATES

Stay up to date on the latest thinking in clinical care and patient guidance.

View all Articles

Nearly 50% Skip Prescribed Breast Cancer Meds; Physicians Should Focus On Cost Cutting and Education

A new study suggests that cost-reduction policies and targeted interventions significantly increase adjuvant endocrine therapy adherence among breast cancer survivors.

Learn More

Study: Physicians Should Prioritize Weight Management in Breast Cancer Care to Boost Survival Rates

A new study underscores the importance of weight counseling in breast cancer. Gains and losses are associated with lower chance of survival, especially in patients who undergo chemotherapy.

Learn More

Integrating Venetoclax Into CLL Management Is Expanding Treatment Horizons and Improving Survival

Clinical Relevance: Venetoclax can offer your CLL patients a powerful, targeted treatment that is personalized and more effective care with fewer side effects than many other options. _________________________________________________________________________________________________________ Oncologists treating chronic lymphocytic leukemia (CLL) and select small lymphocytic lymphomas should strongly consider adding Venetoclax (Venclexta) to their arsenal, given its proven capacity to significantly enhance […]

Learn More

Breaking Down the PAOLA Trial — Who Benefits from Olaparib (Lynparza)?

In the PAOLA trial, ovarian cancer patients received either bevacizumab alone or bevacizumab plus olaparib (brand name: Lynparza) after their frontline therapy. “And what they found in this trial was very interesting,” says Dr. John Nakayama, gynecologic oncologist with Allegheny Health Network in Pittsburgh.

Learn More

PARP Inhibitors Boost Survival in Ovarian Cancer, Prompting New ASCO Guidelines on Their Use

PARP inhibitors are a class of drugs that inhibit one of the backup systems of DNA damage repair. Ovarian cancers with BRCA1, BRCA2, or certain other mutations have a defect in a major DNA damage repair pathway and are highly dependent on secondary pathways for their survival.

Learn More

Decision Making Around PARP Inhibitors Such as Olaparib (Lynparza) in Frontline Maintenance

The typical treatment for patients with advanced ovarian cancer is surgery plus platinum-based chemotherapy. Although most patients go into remission following this regimen, an estimated 70% relapse within the next three years.

Learn More

Should PARP Inhibitors Be Offered to All Women?

When it comes to PARP inhibitors, Dr. Rebecca Arend of the University of Alabama says, “The message is not that each patient should get a PARP inhibitor no matter what, but that it is an awareness that we need to put out into the community.”

Learn More

Evaluating Risks versus Benefits of PARP Inhibitors for Ovarian Cancer Patients

Prescribing any medication or course of treatment involves weighing the risks versus the benefits to the patient, but balancing this equation is particularly crucial with cancer drugs which carry significant side effects and toxicity. As the data on treating ovarian cancer with PARP inhibitors becomes more promising and their use becomes more widespread, oncologists are looking for information on patient tolerance.

Learn More

To Treat Ovarian Cancer With PARP Inhibitors or Not: Factoring the Progression-Free Survival Benefit and Side Effects Into the Decision

PARP inhibitors like niraparib (Zejula) are an effective tool against ovarian cancer. The NOVA trial established that niraparib as maintenance therapy in platinum-sensitive patients significantly improved progression-free survival compared to placebo, regardless of women's BRCA or homologous recombination deficiency (HRD) status. Then, the PRIMA study found the treatment extended PFS in patients with newly diagnosed ovarian cancer, with or without HRD deficiency.

Learn More

Our Mission

Progress through collective wisdom and collaborative energy

Oncologists around the country told us they needed a better way to stay up to date and find support, so we created SurvivorNet Connect. It's a digital platform dedicated to advancing the science and practice of oncology by providing health care providers with a fresh perspective on professional education.

Events & Conferences

Collaborative Workshops

Thought Leadership

“Bringing health care professionals together in a collaborative independent environment is one of the most important things we can do to make an outsize impact”

- Steve Alperin - Founder/CEO SurvivorNet